Seppälä K, Korttila K, Häkkinen S, Linnoila M
Br J Clin Pharmacol. 1976 Oct;3(5):831-41. doi: 10.1111/j.1365-2125.1976.tb00635.x.
Psychomotor skills and visual functions related to driving were measured double-blind cross-over in ten healthy volunteers before, and 1,3,5 and 7 h after a single oral administration of diazepam (10mg), medazepam (15 mg) or lorazepam (2.5 mg). The late effects of lorazepam were tested in seven other subjects 12 and 24 h after the administration. Lorazepam impaired almost all the measured skills more (P less than 0.05 to 0.001) than diazepam, medizepam or the placebo. The lorazepam impairment of reactive skills and flicker fusion discrimination remained statistically significant (P less than 0.05) for as long as 12 h. Medazepam impaired only reactive skills and flicker fusion, the latter remaining impaired (P less than 0.05) for as long a 5 h after the administration. The magnitude and duration of the effects of diazepam were intermediate between those of lorazepam and medazepam. Diazepam impaired perceptual speed and reactive and co-ordinative skills as well as flicker fusion discrimination and visual parameters related to driving. Slight impairments in performance were measurable for up to 5 h after administration but at 7 h the results resembled those measured after the placebo. The lack of alterations in adaptation to darkness, sensitivity to brightness or visual discrimination ability in bright counterlight at a time when flicker fusion discrimination was severely depressed suggests that an impaired ability to discriminate flickering light is of no or little clinical significance to driving ability. It is concluded that patients receiving a 2.5 mg dose of lorazepam should not drive or operate machinery for 24 h after the administration. After diazepam (10 mg) or medazepam (15 mg) patients should refrain from driving or participating inskilled performances for only 5 to 7 hours.
在10名健康志愿者单次口服地西泮(10毫克)、美达西泮(15毫克)或劳拉西泮(2.5毫克)之前以及服药后1、3、5和7小时,采用双盲交叉法测量与驾驶相关的精神运动技能和视觉功能。在另外7名受试者中,于服药后12和24小时测试劳拉西泮的后期效应。与地西泮、美达西泮或安慰剂相比,劳拉西泮对几乎所有测量技能的损害更大(P小于0.05至0.001)。劳拉西泮对反应技能和闪光融合辨别能力的损害在长达12小时内仍具有统计学意义(P小于0.05)。美达西泮仅损害反应技能和闪光融合,服药后长达5小时闪光融合仍受损(P小于0.05)。地西泮效应的程度和持续时间介于劳拉西泮和美达西泮之间。地西泮损害感知速度、反应和协调技能以及闪光融合辨别能力和与驾驶相关的视觉参数。服药后长达5小时可测量到轻微的性能损害,但在7小时时结果类似于服用安慰剂后测得的结果。在闪光融合辨别能力严重下降时,对黑暗适应、对亮度的敏感性或明亮逆光下的视觉辨别能力未发生改变,这表明辨别闪烁光能力受损对驾驶能力无或几乎无临床意义。结论是,服用2.5毫克劳拉西泮的患者在服药后24小时内不应驾驶或操作机械。服用地西泮(10毫克)或美达西泮(15毫克)后,患者仅应在5至7小时内避免驾驶或参与需要技能的活动。